Clinical Trials Logo

Lyme Neuroborreliosis clinical trials

View clinical trials related to Lyme Neuroborreliosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06392815 Recruiting - Clinical trials for Borrelia Burgdorferi Neuroborreliosis

64Cu-DOTATATE-PET for Lyme Neuroborreliosis

DOTA-LYME
Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the applicability and performance of 64Cu-DOTATATE PET/CT/MR for diagnosis in patients with Lyme neuroborreliosis (LNB). In this prospective, observational cohort study with 64Cu-DOTATATE, the investigators wish to include a total of 50 patients clinically suspected of LNB. The investigators will investigate the diagnostic value of 64Cu-DOTATATE-PET comparing clinically suspected and CSF verified LNB patients with clinically suspected patients without CSF verification. The investigators hypothesize that the information obtained from 64Cu-DOTATATE PET/CT/MRI can improve the diagnostics of LNB as well as that 64Cu-DOTATATE PET/CT/MRI will be able to contribute to the follow-up of patients by adding prognostic information and the risk of persistent symptoms. The application of 64Cu-DOTATATE PET/CT/MRI in the diagnostic work-up of LNB would thus expectedly lead to a more precise diagnosis and risk assessment.

NCT ID: NCT05641116 Recruiting - Physical Activity Clinical Trials

Effectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis.

LyMouv'
Start date: September 14, 2023
Phase: N/A
Study type: Interventional

Lyme borreliosis, commonly known as Lyme disease, has been clinically described for more than a century, but has been officially recognized for 40 years, with the detection of the Borrelia bacterium by W. Burgdorfer, in ticks of the Ixodes ricinus complex, identified a few years before.

NCT ID: NCT05625100 Recruiting - Lyme Borreliosis Clinical Trials

Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis

CXCL13-LYME
Start date: July 13, 2020
Phase:
Study type: Observational

Neuroborreliosis (NBL) is diagnosed in 10-15% of patients with Lyme borreliosis. In Europe in adults, the main clinical manifestation is called "Bannwarth syndrome". This includes painful meningoradiculitis, sometimes accompanied by cranial nerve neuritis. Current European guidelines issued by the European Federation of Neurological Societies (EFNS) recommend the following triad for the diagnosis of "definite NBL": (i) Neurological symptoms suggestive of NBL without any other obvious cause; (ii) CSF pleocytosis; (iii) Intrathecal production of specific anti-Borreliella antibodies. CXCL13, C-X-C chemokine motif ligand 13, is a chemokine implicated in B cell chemotaxis. Extensive literature exists on the analysis of CXCL13i as a diagnostic marker for acute NBL. A recent meta-analysis from 2018, published by Rupprecht et al finds an overall sensitivity and specificity of 89% and 96% respectively, indicating satisfactory diagnostic value. In this study, the investigators wish to assess the place of this new marker in the diagnosis of neuroborreliosis before proposing it as a test carried out by the Borrelia CNR.

NCT ID: NCT00910533 Recruiting - Clinical trials for Nervous System Lyme Borreliosis

Study on Early Lyme Neuroborreliosis

Start date: January 1, 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.